Privium Fund Management B.V. Acquires Shares of 173,516 Viridian Therapeutics, Inc. $VRDN

Key Points

• Privium Fund Management acquired a new stake of 173,516 shares in Viridian Therapeutics (~$5.4M), representing about 0.18% of the company and making VRDN its 21st largest holding.
• Investor sentiment has strengthened after positive Phase 3 REVEAL‑2 topline results for elegrobart, an approaching PDUFA for veligrotug, and Q1 results that beat EPS and revenue expectations (≈96% YoY growth).
• However, Viridian announced a concurrent public offering — planned $150M in convertible notes plus $100M of equity — which is dilutive and could limit near‑term upside as the market digests potential share issuance.

Privium Fund Management B.V. acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 173,516 shares of the company's stock, valued at approximately $5,400,000. Viridian Therapeutics accounts for approximately 1.0% of Privium Fund Management B.V.'s holdings, making the stock its 21st largest holding. Privium Fund Management B.V. owned about 0.18% of Viridian Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. US Bancorp DE increased its stake in shares of Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company's stock worth $53,000 after purchasing an additional 463 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock worth $669,000 after purchasing an additional 876 shares during the period. Sei Investments Co. increased its stake in shares of Viridian Therapeutics by 10.0% during the third quarter. Sei Investments Co. now owns 11,556 shares of the company's stock worth $249,000 after purchasing an additional 1,046 shares during the period. Knights of Columbus Asset Advisors LLC increased its stake in shares of Viridian Therapeutics by 2.4% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company's stock worth $1,282,000 after purchasing an additional 1,386 shares during the period. Finally, Arizona State Retirement System increased its stake in shares of Viridian Therapeutics by 8.7% during the fourth quarter. Arizona State Retirement System now owns 18,324 shares of the company's stock worth $570,000 after purchasing an additional 1,460 shares during the period.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Positive topline Phase 3 REVEAL‑2 results for elegrobart in chronic thyroid eye disease (TED); the outcome supports the drug’s efficacy in the chronic patient population and is the main catalyst behind the rally. Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
• Positive Sentiment: PDUFA for veligrotug (TED program) is approaching and management says the company is “launch ready”; investors are re‑rating VRDN on the combination of strong late‑stage data plus an imminent regulatory decision. PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results
• Positive Sentiment: Q1 results: EPS better than expected (loss of $0.90 vs. consensus -$1.06) and revenue topped estimates with ~96% YoY revenue growth — reassures investors about near‑term execution and reduces the “worse‑than‑expected” downside risk. Viridian Q1 2026 Results (Press Release)
• Neutral Sentiment: Trading activity: shares were temporarily halted for “news pending” before the open and volume spiked well above the average — a sign of event‑driven trading rather than a sustained change in fundamentals. (news halt noted by exchange)
• Negative Sentiment: Concurrent public offering announced: planned $150M convertible notes plus $100M of common stock (and preferred) — raises funding but is dilutive and could cap near‑term upside as the market digests potential share/equity dilution. Viridian Therapeutics Announces Proposed Concurrent Public Offerings

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $18.77 on Wednesday. The stock's fifty day moving average price is $22.03 and its two-hundred day moving average price is $27.03. Viridian Therapeutics, Inc. has a one year low of $11.76 and a one year high of $34.29. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. The firm has a market cap of $1.93 billion, a PE ratio of -5.71 and a beta of 0.82.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. During the same quarter last year, the company earned ($0.87) EPS. The company's revenue was up 95.8% on a year-over-year basis. As a group, research analysts expect that Viridian Therapeutics, Inc. will post -3.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VRDN. Needham & Company LLC lowered their target price on Viridian Therapeutics from $42.00 to $32.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Viridian Therapeutics in a research note on Monday, April 20th. HC Wainwright lowered their target price on Viridian Therapeutics from $34.00 to $22.00 and set a "buy" rating on the stock in a research note on Tuesday, March 31st. Wedbush lowered their target price on Viridian Therapeutics from $37.00 to $31.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 8th. Finally, Wells Fargo & Company lowered their target price on Viridian Therapeutics from $29.00 to $20.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 31st. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $37.07.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.